MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 7,939 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 5.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 165,062 shares of the company’s stock after acquiring an additional 7,939 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Recursion Pharmaceuticals were worth $1,116,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of RXRX. Private Trust Co. NA bought a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $27,000. Farther Finance Advisors LLC boosted its position in Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares during the period. NewEdge Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock valued at $53,000 after purchasing an additional 2,387 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Recursion Pharmaceuticals by 220.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company’s stock valued at $66,000 after purchasing an additional 6,758 shares during the period. Finally, Colonial River Investments LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth about $68,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on RXRX. Needham & Company LLC lowered their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Morgan Stanley dropped their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Finally, Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $7.60.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $4.08 on Monday. The firm has a market cap of $1.66 billion, a PE ratio of -2.67 and a beta of 0.99. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock’s fifty day moving average price is $5.14 and its two-hundred day moving average price is $6.50. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period last year, the company posted ($0.39) earnings per share. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.